Industry insights

Why a data and privacy strategy empowers genomics

As we stand on the brink of the personalized medicine era, breakthroughs in areas like genomics are opening up a whole new range of privacy, reliability and security issues. Embedding security and privacy within strategy empowers Life Sciences companies.

Genomics – a blueprint for successful outcomes?

This month marks the 16th anniversary of the first full publication of the human genome. Far from being old news, the potential of genomics continues to grow. In what’s already a period of transformation for Life Sciences companies, how can they drive value from genomics, and what are the pitfalls to be avoided?
3 1

Refining relabeling of pharmaceuticals

Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.
1

Swiss manufacturing and i4.0: The time for experimenting is ending

The fourth industrial revolution has arrived. But Swiss manufacturers are not keeping pace with the speed of transformational change it brings. This represents a real danger to the country’s industrial base.
1

Das Rennen um die Technologieführerschaft

Die Vernetzung und Digitalisierung der Steuerung von Fahrzeugen sowie der Wettbewerb der bevorzugten Antriebstechnologien sind derzeit die grössten Megatrends und Innovationstreiber der globalen Automobilindustrie. Gleichzeitig nimmt der Anteil Europas an der weltweiten Automobilproduktion weiter ab.

Swiss Life Sciences – ready for R&D 2030?

Digitalization and societal shifts are pushing Life Sciences to the brink of transformation. Over the next decade, successful players will need to redefine their R&D activities in order to rein in expenses, respond to shorter product lifecycles and seize opportunities of personalized medicine.
3